AI Article Synopsis
- This research investigates the connection between sleep disorders (SD) and major depressive disorder (MDD), focusing on how SD impacts cognitive function.
- The study included 372 MDD patients and 457 healthy controls, finding that MDD patients are 38.88 times more likely to have a sleep disorder compared to healthy individuals.
- Results suggest that sleep disorders contribute to greater impairment in visuospatial and constructional abilities among MDD patients, and improving sleep quality and addressing depression can help mitigate these cognitive deficits.
Article Abstract
Background: This research aims explored the sleep disorder (SD) role in major depressive disorder (MDD), and the SD influencing their cognition.
Methods: 372 MDD patients and 457 healthy controls (HCs) were enrolled.
Results: Patients increased a 38.88 times SD risk compared with HCs. In patients, visuospatial/constructional score was lower in SD than non-SD, and PSQI score was negatively associated with visuospatial/constructional score of SD. In SD and non-SD, RBANS scores were lower in MDD than HCs, excepted for visuospatial/constructional in non-SD.
Conclusion: The SD as a MDD risk factor, has more serious visuospatial/constructional impairment alleviated via improving sleep/depression in patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajp.2022.103228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sleep difficulties related to psychopathology and neurocognition in people with 22q11.2 deletion syndrome.
Psychiatry Res
December 2024
Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Brain Behavior Laboratory, Neuropsychiatry Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:
The 22q11.2 Deletion Syndrome (22q11.2DS) is a multisystem genetic disorder with prominent sleep disturbances, neuropsychiatric conditions and neurocognitive challenges.
View Article and Find Full Text PDFPreliminary examination of orexin receptor antagonism with suvorexant in individuals with Methamphetamine use disorder: a case series study.
J Addict Dis
December 2024
Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.
No FDA-approved medications for methamphetamine (MA) use disorder (MUD) are available. Suvorexant (SUVO), a dual orexin receptor antagonist that is FDA approved for insomnia treatment, reduces MA self-administration and MA-induced reinstatement responding in preclinical studies. SUVO may also reduce MA use by targeting substance use risk factors, including insomnia, stress, cue reactivity, and craving.
View Article and Find Full Text PDF[Breathing disorders during sleep in patients with dystrophic myotonia].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Republican Scientific and Practical Center of Neurology and Neurosurgery, Minsk, Belarus.
Objective: To analyze the results of nocturnal breathing parameters during sleep based on nocturnal pulse oximetry and to study of characteristics of external respiration in genetically confirmed patients with dystrophic myotonia (DM).
Material And Methods: The subjects of the study were patients with genetically confirmed DM types 1 and 2 who were hospitalized in the neurological departments of the Republican Scientific and Practical Center for Neurology and Neurosurgery. The clinical picture of the disease, comorbidities, sleep questionnaires, laboratory tests, overnight pulse oximetry and spirometry were performed and analyzed.
[Subjective sleep quality evaluation in patients with neuromyelitis optica spectrum disorders].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Yaroslavl State Medical University, Yaroslavl, Russia.
Objective: To analyze the subjective sleep assessment in patients with neuromyelitis optica spectrum diseases (NMOSD) according to the current disease criteria of 2015.
Material And Methods: Twenty patients (17 women and 3 men), median age 44.5 years [Q:Q=27.
Prediction of Phenoconversion into Alpha-Synucleinopathy in Patients with isolated REM Sleep Behavior Disorder Using Event-Related Potentials During Visuospatial Attention Tasks.
Sleep
December 2024
Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Study Objectives: Isolated REM sleep behavior disorder (iRBD) is recognized as a prodromal stage of alpha-synucleinopathies. Predicting phenoconversion in iRBD patients remains a key challenge. We aimed to investigate whether event-related potentials (ERPs) recorded during visuospatial attention task can serve as predictors of phenoconversion in iRBD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!